

Regimen Reference Order – LYMP – oBINutuzumab maintenance

Planned Course: Every 8 weeks for 12 doses (2 years)

Indication for Use: Non-Hodgkin Lymphoma

CVAD: At Provider’s Discretion

Proceed with treatment if:

ANC equal to or greater than $1 \times 10^9/L$ AND Platelets equal to or greater than $75 \times 10^9/L$

❖ **Contact Hematologist if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – LYMP – oBINutuzumab maintenance

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
dexamethasone	20 mg	ONLY to be given if patient had a grade 3 or 4 infusion-related reaction with their previous oBINutuzumab infusion or if their lymphocyte count is greater than $25 \times 10^9/L$ IV in normal saline 50 mL over 15 minutes 1 hour prior to oBINutuzumab as needed <i>*Nursing Alert: oBINutuzumab starts 1 hour after completion of dexamethasone infusion</i>
diphenhydrAMINE	50 mg	ONLY to be given if patient experienced any infusion-related reaction with previous oBINutuzumab infusion IV in normal saline 50 mL over 15 minutes 30 minutes prior to oBINutuzumab as needed
acetaminophen	650 mg	Orally 30 minutes prior to oBINutuzumab
oBINutuzumab	1000 mg	IV in normal saline 250 mL following administration rates below: <ul style="list-style-type: none"> • 0 to 30 minutes – 25 mL/hour • 30 to 60 minutes – 50 mL/hour • 60 to 90 minutes – 75 mL/hour • 90 minutes onwards – 100 mL/hour <i>*Alert: Pharmacy to ensure final volume in bag = 250 mL (4 mg/mL final concentration)</i> <i>*Nursing Alert: Line will be primed with oBINutuzumab</i>

Flush after each medication:

- 50 mL over 6 minutes (500 mL/hr)

In the event of an infusion-related hypersensitivity reaction, refer to the ‘Hypersensitivity Reaction Standing Order’

REQUIRED MONITORING

All Cycles

- CBC, biochemistry as per physician order
- Full vital signs (temperature, heart rate, respiration, blood pressure and O₂ saturation) at baseline and as clinically indicated

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
Not Applicable		

DISCHARGE INSTRUCTIONS

- N/A

ADDITIONAL INFORMATION

- Administering nurse must document any infusion related-reactions with any dose of oBINutuzumab